The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies.

The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies. Surg Oncol Clin N Am. 2019 Jul;28(3):369-386 Authors: Keung EZ, Wargo JA Abstract Immunotherapy has led to unprecedented improvement in the treatment and prognosis of high-risk resectable and metastatic disease across cancer types. Nowhere is this better highlighted than in the management of advanced and metastatic melanoma with the introduction of molecularly targeted therapies and immune checkpoint inhibitors. Following their success in melanoma, immunotherapies have also been evaluated and their use approved in the management across a variety of other solid malignancies in the neoadjuvant, adjuvant, and advanced/metastatic setting. This review provides an overview of the current landscape of immune checkpoint inhibition for solid malignancies. PMID: 31079794 [PubMed - in process]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Surg Oncol Clin N Am Source Type: research